Chemical inhibitors of MAGE-C3 can exert their influence by targeting critical components of signaling pathways that are essential for the protein's function. Dabrafenib, a BRAF inhibitor, can inhibit MAGE-C3 by interrupting the BRAF/MEK/ERK pathway, which is known to be essential for the post-translational modification or stabilization of various proteins, including the MAGE family. Similarly, Trametinib and Cobimetinib function as MEK inhibitors and can inhibit MAGE-C3 by disrupting downstream signaling of the RAS/RAF/MEK/ERK pathway, which is central to the regulation of protein activity within the cell. Vemurafenib, another BRAF inhibitor, can inhibit MAGE-C3 by obstructing the kinase activity necessary for its function or stability. LY3009120, targeting pan-RAF kinases, can inhibit MAGE-C3 by halting the RAF/MEK/ERK signaling cascade, thereby affecting proteins directly regulated by this pathway.
Encorafenib, as a BRAF inhibitor, can inhibit MAGE-C3 by interfering with MAPK pathway signaling mechanisms that MAGE-C3 may utilize. Binimetinib can inhibit MAGE-C3 by preventing MEK activation, thus impeding the signaling pathways that regulate MAGE-C3 activity. Sorafenib's multitargeted kinase inhibition can inhibit MAGE-C3 by disrupting various pathways, some of which may contribute to the post-translational modifications of MAGE-C3. Sunitinib, a receptor tyrosine kinase inhibitor, can inhibit MAGE-C3 by blocking critical signaling pathways that underpin the functional stability of proteins. Selumetinib, by specifically inhibiting MEK1/2, can inhibit MAGE-C3 by obstructing the MEK/ERK pathway, potentially a requirement for MAGE-C3's activity. Additionally, Pazopanib and Lenvatinib, as multikinase inhibitors, can inhibit MAGE-C3 by disrupting signal transduction through pathways involving receptor tyrosine kinases, which might be important for the regulation and function of MAGE-C3. These chemicals act on precise molecular targets within signaling cascades that are known to be important for the function of proteins such as MAGE-C3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib is a BRAF inhibitor that can inhibit MAGE-C3 by disrupting the BRAF/MEK/ERK pathway, which MAGE-C3 may utilize for post-translational modifications or stabilization. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that can inhibit MAGE-C3 by impeding the downstream signaling of the RAS/RAF/MEK/ERK pathway, which is involved in the regulation of numerous proteins including MAGE family proteins. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib selectively inhibits MEK1/2, potentially leading to decreased MAGE-C3 function by interfering with its associated signaling pathways that rely on MEK/ERK phosphorylation events. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib targets BRAF V600E kinase, which can result in the inhibition of MAGE-C3 by blocking the pathway needed for its activity or expression stabilization. | ||||||
LY3009120 | 1454682-72-4 | sc-507538 | 5 mg | $125.00 | ||
LY3009120 inhibits pan-RAF kinases and can inhibit MAGE-C3 function by halting the RAF/MEK/ERK signaling cascade, affecting proteins regulated by this pathway. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Encorafenib is a BRAF inhibitor which can inhibit MAGE-C3 by disrupting the normal signaling mechanisms in which MAGE-C3 might participate, particularly the MAPK pathway. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Binimetinib, a MEK inhibitor, can inhibit MAGE-C3 by preventing the activation of MEK proteins, thus impeding the signaling pathways that could regulate MAGE-C3 activities. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases and can inhibit MAGE-C3 by disrupting various signaling pathways, including those that might contribute to MAGE-C3 post-translational modification. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib is a receptor tyrosine kinase inhibitor that can inhibit MAGE-C3 by blocking signaling pathways that are critical for the function and stability of various proteins, possibly including MAGE-C3. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a selective, non-ATP-competitive inhibitor of MEK1/2 that can inhibit MAGE-C3 by obstructing the MEK/ERK pathway, which may be necessary for MAGE-C3's functional role. | ||||||